PFG Investments’s Verve Therapeutics VERV Stock Holding History

PFG Investments’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-10,900	Closed	-$52.8K	–	1079
2024 Q3	$52.8K	Buy	+10,900	New	+$63.3K	﹤0.01%	967

Other funds holding VERV

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

PFG Investments's VERV Position: Q4 2024 in Review

PFG Investments sold out of Verve Therapeutics (VERV) in Q4 2024, closing a stake of 10,900 shares — an estimated $52.8K sold.

PFG Investments first reported a position in VERV in Q3 2024 and held it in 1 quarter. The position peaked at $52.8K in Q3 2024. 166 funds tracked by Wall St. Rank hold VERV as of Q4 2024.

PFG Investments reported no remaining Verve Therapeutics position as of Q4 2024 after selling out during the quarter.
PFG Investments sold 10,900 Verve Therapeutics shares in Q4 2024, an estimated $52.8K.
PFG Investments first reported a position in Verve Therapeutics in Q3 2024 and held it in 1 quarter.
PFG Investments's Verve Therapeutics position peaked at $52.8K in Q3 2024.
166 funds tracked by Wall St. Rank held Verve Therapeutics as of Q4 2024.

Based on PFG Investments's 13F filing for Q4 2024, filed 22 Jan 2025.